AK2

Across TCGA pan-cancer cohorts, AK2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AK2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AK2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AK2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

HNSC, PDAC, and COAD are the cancer types where AK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	0.472	0.779	.003	48	view →
PDAC	OS	Tertile	III,IV	0.977	0.360	.005	41	view →
COAD	DFS	Median	III,IV	1.000	0.838	.036	24	view →
GBM	OS	Median	All	0.409	0.654	.003	11	view →
LUAD	OS	Median	III,IV	0.670	0.219	.007	7	view →
CCRCC	DFS	Median	III,IV	0.459	0.742	.019	7	view →
LSCC	DFS	Quartile	All	0.935	1.000	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AK2–HNSC (DFS)

Open the HNSC breakdown →